Overcoming Barriers to Mucosal Vaccination: From Adjuvant Concepts to Probiotic Spores and Cochleate as Innovative Approaches
Authors:
- Belkis RomeuBelkis Romeu
- Laura Maria ReyesLRLaura Maria Reyes
- Miriam LastreMLMiriam Lastre
- Raúl Ramos PupoRPRaúl Ramos Pupo
- Julio BalboaJBJulio Balboa
- Dainerys Aleida Pérez-LastreDPDainerys Aleida Pérez-Lastre
- Maykel Lazel Rocha-QuintanaMRMaykel Lazel Rocha-Quintana
- Alexis LabradaALAlexis Labrada
- Ormany Soriano-TorresOrmany Soriano-Torres
- Angel Juztiz VaillantAVAngel Juztiz Vaillant
- Pia GattingerPGPia Gattinger
- Guillermo DocenaGDGuillermo Docena
Preprint
- 30 October 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background. Mucosal vaccination offers the possibility of establishing immune protection directly at portals of pathogen entry, but its development remains constrained by biological, technological, and implementation barriers. Objective. To integrate the major challenges limiting mucosal vaccination within a common framework and examine emerging strategies capable of addressing several of these barriers simultaneously. Results and Discussion. We consider six interconnected challenges: incomplete recognition of the determinant role of adjuvants; scarcity of safe and accessible mucosal adjuvants; the need to overcome mucosal tolerance while preserving tissue homeostasis; dependence on coldchain logistics; reliance on multidose immunization schedules to achieve protective immunity; and limited breadth of vaccine-induced cross-reactive protection. To better capture the complexity of modern vaccine platforms, we discuss expand adjuvant activity as exogenous, self-adjuvanting, or endogenous according to the origin of the immunostimulatory signal. Particular emphasis is placed on proteoliposome- and cochleate-based systems and probiotic Bacillus subtilis spores as multifunctional platforms combining antigen delivery with intrinsic immunostimulatory properties. Preclinical studies support their capacity to induce systemic IgG, mucosal secretory IgA, cellular responses, and memory response, while their heat resistance may facilitate the development of more thermostable formulations. We also discuss the Single Time Vaccination Strategy as an approach to combined-route immunization and consider glycans and other microbial structures as potential contributors to antigen-specific and cross-reactive mucosal responses. Conclusions. Future mucosal vaccine development should consider adjuvants as tools for coordinated antigen delivery, innate sensing, immune programming with polarization activity, and mucosal memory rather than solely as immune potentiators and delivery system. Probiotic spores, cochleates, and combined-route strategies provide promising examples of this integrated approach, although their translational value will require rigorous demonstration of formulation stability, mechanisms of action, safety, protective breadth, and clinical efficacy.Keywords
All Related Versions
This publication has 99 references indexed in Scilit:
- Programming systemic and mucosal immunity through co-adjuvant-based prime-boost vaccinationCurrent Opinion in Virology, 2026
- The Role of IgA in the Manifestation and Prevention of Allergic Immune ResponsesCurrent Allergy and Asthma Reports, 2023
- Influence of Microbiota on Vaccine Effectiveness: “Is the Microbiota the Key to Vaccine-induced Responses?”Journal of Microbiology, 2023
- VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patientsCancer Immunology, Immunotherapy, 2022
- The Impact of the Microbiome on Immunity to Vaccination in HumansCell Host & Microbe, 2020
- BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained ImmunityCell Host & Microbe, 2018
- The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltrationBiomaterials, 2016
- Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide AImmunologic Research, 2013
- Alum adjuvanticity: Unraveling a century old mysteryEuropean Journal of Immunology, 2008
- Natural endogenous adjuvantsSpringer Seminars in Immunopathology, 2004